Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Ben Jemaa, Awatef ^a   Bouraoui, Yosra ^a   Sallami, Sataa ^b   Banasr, Ahmed ^c   Rais, Nawfel Ben ^d   Ouertani, Latifa ^e   Nouira, Yassin ^b   Horchani, Ali ^b   Oueslati, Ridha ^a  

^a UNIVERSITY OF CARTHAGE   (Tunisia)

^b LA RABTA HOSPITAL   (Tunisia)

^c CHARLES NICOLLE HOSPITAL   (Tunisia)

^d MILITARY HOSPITAL OF TUNIS   (Tunisia)

^e Department of Anathomopathology   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIBODY; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANGIOGENESIS; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT TRANSFORMATION; PATHOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; TUMOR GROWTH; VASCULARIZATION; BIOSYNTHESIS; METABOLISM; MIDDLE AGED; PROSTATE TUMOR;

AGED; AGED, 80 AND OVER; ANTIGENS, SURFACE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 78650542926     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-171     Document Type: Article

References (45)

1. Comparison of the zones of the human prostate with the seminal vesicle: morphology, immunohistochemistry, and cell kinetics. I Laczká DL Hudson A Freeman MR Feneley JR Masters, Prostate 2005 62 260 266 15389778
2. Gene expression profiling of the human prostate zones. L Van der Heul-Nieuwenhuijsen PJM Hendriksen TH Van der Kwast G Jenster, BJU Int 2006 98 886 897 10.1111/j.1464-410X.2006.06427.x 16978289
3. Epithelial stem cells in human prostate growth and disease. DL Hudson, Prostate Cancer Prostatic Dis 2004 7 188 194 10.1038/sj.pcan.4500745 15289813
4. Biomarkers of Growth, Differentiation, and Metastasis of Prostate Epithelium. ET Keller C Hall J Dai L Wallner, Journal of Clinical Ligand Assay 2004 27 133 136
5. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. RS Israeli CT Powell WR Fair WD Heston, Cancer Res 1993 53 227 230 8417812
6. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. MI Milowsky DM Nanus L Kostakoglu CE Sheehan S Vallabhajosula SJ Goldsmith JS Ross NH Bander, J Clin Oncol 2007 25 540 547 10.1200/JCO.2006.07.8097 17290063
7. Structure of membrane glutamate carboxypeptidase. ND Rawlings AJ Barrett, Biochim Biophys Acta 1997 1339 247 252 9187245
8. Analysis of glycosylation of prostate-specific membrane antigen derived from LNCaP cells, prostatic carcinoma tumors, and serum from prostate cancer patients. EH Holmes TG Greene WT Tino AL Boynton HC Aldape SL Misrock GP Murphy, Prostate Suppl 1996 7 25 29 10.1002/(SICI)1097-0045(1996)7+<25::AID- PROS3>3.0.CO;2-I 8950359
9. Amino acids at the N-and C-termini of human glutamate carboxypeptidase II are required for enzymatic activity and poper folding. C Barinka P Micochova P Sacha I Hilgert P Majer BS Slusher V Horejsí J Konvalinka, Eur J Biochem 2004 271 2782 2790 10.1111/j.1432-1033.2004.04209.x 15206943
10. Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients. TD Schmittgen S Teske RL Vessella LD True BA Zakrajsek, Int J Cancer 2003 107 323 329 10.1002/ijc.11402 12949815
11. High expression of PSM-E correlated with tumor grade in prostate cancer: a new alternatively spliced variant of prostate-specific membrane antigen. KY Cao XP Mao DH Wang L Xu GQ Yuan SQ Dai BJ Zheng SP Qiu, Prostate 2007 67 1791 1800 10.1002/pros.20664 17929272
12. Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. RG Lapidus CW Tiffany JT Isaacs BS Slusher, Prostate 2000 45 350 354 10.1002/1097-0045(20001201)45:4<350::AID-PROS10>3.0.CO;2-U 11102961
13. Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity. G Anilkumar SA Rajasekaran S Wang O Hankinson NH Bander AK Rajasekaran, Cancer Res 2003 63 2645 2648 12750292
14. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine. RL Sokoloff KC Norton CL Gasior KM Marker LS Grauer, The Prostate 2000 43 150 157 10.1002/(SICI)1097-0045(20000501) 43:2<150::AID-PROS10>3.0.CO;2-B 10754531
15. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. RE Carter AR Feldman JT Coyle, Proc Natl Acad Sci 1996 93 749 753 10.1073/pnas.93.2.749 8570628
16. Expression of Prostate Specific Membrane Antigen (PSMA), Increases Cell Folate Uptake and Proliferation and Suggests a Novel Role for PSMA in the Uptake of the Non-Polyglutamated Folate, Folic Acid. Y Veronica EB Clifford KC Joseph DS O'Keefe DJ Bacich, Prostate 2010 70 305 316 19830782
17. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. S Perner MD Hofer R Kim RB Shah H Li P Möller RE Hautmann JE Gschwend R Kuefer MA Rubin, Hum Pathol 2007 38 696 70 10.1016/j.humpath.2006.11.012 17320151
18. Prostate-specific membrane antigen expression in normal and malignant human tissues. DA Silver I Pellicer WR Fair WD Heston C Cordon-Cardo, Clin Cancer Res 1997 3 81 85 9815541
19. The new human tissue kallikrein gene family: structure, function, and association to disease. GM Yousef EP Diamandis, Endocr Rev 1992 22 184 204 10.1210/er.22.2.184
20. Hormone resistant prostatic adenocarcinoma. An evaluation of prognostic factors in pre- and post-treatment specimens. A Berner JM Nesland H Waehre J Silde SD Fosså Br J Cancer 1993 68 380 384 7688548
21. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. H Lilja A Christensson U Dahlén MT Matikainen O Nilsson K Pettersson T Lövgren, Clin Chem 1991 37 1618 1625 1716536
22. Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? SA Williams P Singh JT Isaacs SR Denmeade, Prostate 2007 67 312 329 10.1002/pros.20531 17143882
23. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. JE Oesterling, J Urol 1991 145 907 923 1707989
24. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas. R Stege M Grande K Carlström B Tribukait A Pousette, Clin Cancer Res 2000 6 160 165 10656445
25. Prognostic significance of angiogenesis in clinically localized prostate cancer (staining for Factor VIII-related antigen and CD34 Antigen. A Arakawa S Soh S Chakraborty PT Scardino TM Wheeler, Prostate Cancer and Prostatic Dis 1997 1 32 38 10.1038/sj.pcan.4500204
26. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. RE Conway N Petrovic Z Li W Heston D Wu LH Shapiro, Mol Cell Biol 2006 26 5310 5324 10.1128/MCB.00084-06 16809768
27. Immunohistochemical characterization of prostate specific membrane antigen expression in the vasculature of normal and neoplastic tissues. GK Nielson K Sojka K Trumbull B Spaulding R Welcher, Modern Path 2004 17 326A
28. Expression of prostate specific membrane antigen in androgen-independent prostate cancer cell line PC-3. P Laidler J Duliska M Lekka, Arch Biochem Biophys 2005 435 1 14 10.1016/j.abb.2004.12.003 15680901
29. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. JW Moul, Eur Urol 1999 35 399 407 10.1159/000019916 10325496
30. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. S Mannweiler P Amersdorfer S Trajanoski JA Terrett D King G Mehes, Pathol Oncol Res 2009 15 167 172 10.1007/s12253-008-9104-2 18802790
31. Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. HH Heidtmann DM Nettelbeck A Mingels R Jäger HG Welker RE Kontermann, Br J Cancer 1999 81 1269 1273 10.1038/sj.bjc.6692167 10604721
32. Tumor Angiogenesis Is Associated with MUC1 Overexpression and Loss of Prostate-specific Antigen Expression in Prostate Cancer. E Sivridis A Giatromanolaki MI Koukourakis, Clin Cancer Res 2001 7 1533 1538 11410487
33. Advanced prostate cancer. Selected aspects of human pathology, clinical oncology and epidemiology. E Hernes, Faculty of Medicine, Oslo 2005
34. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. DG Bostwick A Pacelli M Blute P Roche GP Murphy, Cancer 1998 82 2256 2261 10.1002/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S 9610707
35. Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis. AF Neves TG Arajo WK Biase J Meola TM Alcntara DG Freitas LR Goulart, Clin Biochem 2008 41 1191 1198 10.1016/j.clinbiochem.2008.06.013 18640109
36. Biology of Prostate-specific antigen. SP Balk YJ Ko GJ Bubley, Journal of Clinical Oncology 2003 21 383 391 10.1200/JCO.2003.02.083 12525533
37. The Prostate Specific Membrane Antigen Regulates the Expression of IL-6 and CCL5 in Prostate Tumour Cells by Activating the MAPK Pathways. M Colombatti S Grasso A Porzia G Fracasso MT Scupoli S Cingarlini O Poffe HY Naim M Heine G Tridente F Mainiero D Ramarli, Plos One 2009 4 4608 10.1371/journal.pone.0004608 19242540
38. An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines. M Paliouras EP Diamandis, Biol Chem 2008 389 773 780 10.1515/BC.2008.072 18627304
39. 1alpha,25-Dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells. RE Serda M Bisoffi TA Thompson M Ji JL Omdahl LO Sillerud, Prostate 2008 68 773 783 10.1002/pros.20739 18247401
40. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy. K Kuroda H Liu S Kim M Guo V Navarro NH Bander, Prostate 2009 69 1579 1585 10.1002/pros.21004 19575420
41. Dissociation between androgen responsiveness for malignant growth vs expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. SR Denmeade LJ Sokoll S Dalrymple DM Rosen AM Gady D Bruzek RM Ricklis JT Isaacs, Prostate 2003 54 249 257 10.1002/pros.10199 12539223
42. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. GL Wright Jr BM Grob C Haley K Grossman K Newhall D Petrylak J Troyer A Konchuba PF Schellhammer R Moriarty, Urology 1996 48 326 334 10.1016/S0090-4295(96)00184-7 8753752
43. Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis. H Gustavsson K Welén JE Damber, Prostate 2005 62 364 373 10.1002/pros.20145 15389782
44. Correlation between PSMA and VEGF expression as markers for LNCaP tumor angiogenesis. P Tsui M Rubenstein P Guinan, J Biomed Biotechnol 2005 2005 287 290 10.1155/JBB.2005.287 16192687
45. SOCS-3 antagonises the proliferative and migratory effects of FGF-1 2 in prostate cancer by inhibition of p44/p42 MAPK signaling. M Puhr FR Santer H Neuwirt G Marcias A Hobisch Z Culig, Endocr Relat Cancer 2010 17 525 53 10.1677/ERC-10-0007 20335309